NCT06991309

Brief Summary

Head and neck cancer patients are vulnerable to various psychological complications due to the effects of both cancer itself and cancer treatment on patients' appearance and physical well-being. Nevertheless, few data have been obtained on effective psychosocial interventions that could protect this group of cancer patients' psychological well-being. Therefore, this two-armed, parallel-group, double-blind, randomized control trial (RCT) aims to evaluate and compare the effects of mindfulness-based stress reduction (MBSR) on psychosocial complications (depression, anxiety, and internalized stigma) among newly diagnosed head and neck cancer patients. This RCT will target newly diagnosed head and neck cancer patients who have been treated only with surgery or who have not yet received any treatment. In total, 106 patients who meet all of the study's inclusion criteria and none of its exclusion criteria will be randomly assigned into two groups-an MBSR group and a treatment-as-usual control group-at a 1:1' allocation ratio. Participants in the intervention group (MBSR group) will undergo an eight-week group intervention program. During this program, each intervention will comprise eight modules based on MBSR manual. Outcome assessments will be performed across a three-point timeline, including before the intervention (T0), immediately after the psychosocial intervention at eight weeks (T1), and 12 weeks after the intervention (T2). The primary outcome that will be assessed during this RCT is the severity of depression and anxiety. Meanwhile, the secondary outcome that will be evaluated in this study is such as internalized stigma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

May 19, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 27, 2025

Completed
Last Updated

May 31, 2025

Status Verified

May 1, 2025

Enrollment Period

1.5 years

First QC Date

May 19, 2025

Last Update Submit

May 26, 2025

Conditions

Keywords

DepressionAnxietyInternalized stigmahead and neck cancerrandomized controlled trial

Outcome Measures

Primary Outcomes (1)

  • Hospital Anxiety and Depression Scale

    The Malay version of the "Hospital Anxiety and Depression Scale" (HADS) will be used to assess the severity of depression and anxiety symptoms among participants. The HADS is a 14-item, self-rated questionnaire with seven items in each of its subscales. Each item is scored from 0 to 3, and the total score for both the depression and anxiety subscales ranges from 0 to 21 per subscale. The cut-off for depression cases is 8/21, and the cut-off for anxiety cases is also 8/21. The Malay version of the HADS has been validated among Malaysian breast cancer patients, and it exhibited acceptable to good internal consistency for its total score and subscales with Cronbach's alphas ranging from 0.73 to 0.87

    Change of the mean HADS Depression and Anxiety Subscale scores between baseline and 8 weeks of commence of intervention and between 8 weeks of commence of intervention to 12 weeks after completion of intervention

Secondary Outcomes (1)

  • Shame and Stigma Scale

    Change of the mean total SSS scores between baseline and 8 weeks of commence of intervention and between 8 weeks of commence of intervention to 12 weeks after completion of intervention

Study Arms (2)

Mindfulness-based stress reduction group

EXPERIMENTAL

MBSR will be conducted as group sessions, with each session lasts for 2.5 hours, once a week for 8 weeks with another 45 minutes of home practice on daily basis.

Behavioral: MBSR

Treatment-as-usual control group

NO INTERVENTION

The participants in the control group will receive treatment-as-usual in which routine oncology support such as appointment with oncologists or palliative care physicians, general practitioner for usual cancer care. The participants physical health and medications for their cancer treatment will be reviewed and treatment will be modified according to physical symptoms such as pain. Specific psychological interventions such as cognitive behavioral therapy, interpersonal therapy, mindfulness-based interventions, acceptance and commitment therapy, etc will be avoided.

Interventions

MBSRBEHAVIORAL

MBSR will be conducted as group sessions, with each session lasts for 2.5 hours, once a week for 8 weeks with another 45 minutes of home practice on daily basis. The MBSR sessions will be based on therapy format developed by Kabat-Zinn. All the sessions focus on mindfulness practices, sharing of experiences with others, and didactic teaching on stress. Mindfulness practices which will be discussed include body scan exercise, and mindful breathing meditation techniques, three-minute breathing exercises, five-minute seeing or hearing exercises, bodily mindfulness in movement and mindful stretching, yoga and sitting meditation. The therapists will review feedbacks for each session, acknowledge the thoughts, feelings, and senses, examine how participants practice mindfulness, and give assignments to encourage participants to continually practice mindfulness at home. Each participant will receive a CD detailing on meditation practices and a workbook on the mindfulness practices.

Mindfulness-based stress reduction group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • those diagnosed with HNC confirmed by histopathological report and at any stage of cancer
  • those aged 18 years old and above
  • those who have completed surgery and started chemotherapy and/or radiotherapy
  • literate in the Malay language.

You may not qualify if:

  • history of pre-existing psychiatric illnesses (such as psychotic disorder, bipolar disorder, anxiety disorder, depressive disorder, neurodevelopmental disorder, neurocognitive disorder)
  • history of pre-existing medical illnesses which may induce psychiatric symptoms (such as kidney and liver failure, ischemic heart disease, epilepsy, hyperthyroidism, hypothyroidism, Cushing's syndrome, Addison's disease, systemic lupus erythematosus, neurological disorder, rheumatoid arthritis)
  • history of illicit drug and alcohol use
  • pregnancy
  • suicidal tendency
  • those with history of engaged in other psychotherapy
  • those who are not physically and cognitively fit to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pusat Perubatan Universiti Sains Malaysia Bertam

Kepala Batas, Pulau Pinang, 13200, Malaysia

Location

Related Publications (1)

  • Zhang Z, Zhang Q, Lu P, Shari NI, Nik Jaafar NR, Mohamad Yunus MR, Qiu Q, Ismail F, Ab Muin NF, Leong Bin Abdullah MFI. Mindfulness-Based Stress Reduction Alleviates Depression, Anxiety, and Internalized Stigma Compared With Treatment-as-Usual Among Head and Neck Cancer Patients: Findings From a Randomized Controlled Trial. Depress Anxiety. 2025 Sep 11;2025:7499120. doi: 10.1155/da/7499120. eCollection 2025.

MeSH Terms

Conditions

DepressionAnxiety DisordersHead and Neck Neoplasms

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMental DisordersNeoplasms by SiteNeoplasms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

May 19, 2025

First Posted

May 27, 2025

Study Start

January 1, 2022

Primary Completion

June 30, 2023

Study Completion

June 30, 2023

Last Updated

May 31, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Study subjects are vulnerable group of the population and restriction of IPD is part of the requirement of the institutional review board to protect the personal data of the subjects.

Locations